Lead Product(s): Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Highest Development Status: Phase III Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 02, 2020
The agreement is part of MediWound's global commercialization strategy that will expand the medical and commercial potential of NexoBrid to treat skin burns.